Novo Nordisk has invested approximately $126 million in new laboratories at the company's R&D campus in Måløv, Denmark. Construction has started, and the new laboratory facility is expected to be ready in early 2016.

The new facility, Diabetes Research House, will accommodate approximately 350 employees. During the construction phase, the project is expected to generate more than 1,000 jobs outside Novo Nordisk.

"The new lab facility will provide an environment for cutting-edge diabetes research within biotechnology and protein chemistry," said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. "Here our researchers will be working closely together with leading scientists in Denmark and abroad on the discovery and development of new medicines for the treatment of type 1 and type 2 diabetes."

The facility comprises two laboratory wings, a middle building with office space and an auditorium seating 450 people.

Novo Nordisk opened its R&D campus in Måløv in 1991 with about 300 employees. Today the campus accommodates more than 2,300 employees. Globally, about 5,000 employees are involved in R&D activities at Novo Nordisk's R&D units in Denmark, the U.S. and China.